Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Amgen, Inc.

Expert Illustrations & Commentaries™: Harnessing the Power of KRAS Inhibition to Treat Solid Tumors

Release Date: November 15, 2021
Expiration Date: November 15, 2022

Activity Overview

This activity is a video-based program in which 2 experts discuss the emerging use of KRAS inhibitors in cancer. Their discussion is enriched with the use of video animations to illustrate KRAS biology, its role in oncogenesis, and efforts to target mutated forms of the protein. The use of these animated segments helps make complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the management of KRAS-mutant cancers and improve outcomes for their patients.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, pathologists, and fellows involved in the treatment of cancers. Nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Illustrate the biological role of KRAS mutations in solid tumors, including the impact of KRAS targeting on tumor biology
Evaluate recent clinical trial efficacy and safety results concerning KRAS-targeted therapies that have been evaluated in solid tumor settings
Determine effective strategies to monitor and manage adverse events associated with KRAS-targeted therapies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Ramaswamy Govindan, MD
Professor of Medicine
Anheuser Busch Chair in Medical Oncology
Director, Section of Medical Oncology
Division of Oncology
Washington University School of Medicine
St. Louis, MO

Disclosures: Consultant: GenePlus, Inivata, PrecisCa, Merck.

Piro Lito, MD, PhD
Associate Member and Attending Physician
Human Oncology and Pathogenesis Program
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: AAmgen, Mirati, Revolution Medicines, Boehringer Ingelheim; Consultant: Revolution Medicines, Boehringer Ingelheim, Black Diamond, AmMax, Repare

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.